Markus Berger

Dr. Markus Berger

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
WBWalter Orlando Beys-da-Silva
Walter Orlando Beys-da-Silva
RRRafael Lopes da Rosa
Rafael Lopes da Rosa
Lucélia SantiLucélia Santi
Lucélia Santi
ETEmanuela Fernanda Tureta
Emanuela Fernanda Tureta
PTPaula Barros Terraciano
Paula Barros Terraciano
MBMarkus Berger
Markus Berger

1 April 2020 in Reproductive Toxicology
Verified
Journal Article
Closed access
LALaura Silveira Ayres
Laura Silveira Ayres
MBMarkus Berger
Markus Berger
IDIsabel Cirne Lima de Oliveira Durli
Isabel Cirne Lima de Oliveira Durli
CKCristiana Palma Kuhl
Cristiana Palma Kuhl
PTPaula Barros Terraciano
Paula Barros Terraciano
ECElizabeth Obino Cirne-Lima
Elizabeth Obino Cirne-Lima

14 February 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
MBMarkus Berger
Markus Berger
JMJoão Alfredo Moraes
João Alfredo Moraes
WBWalter Orlando Beys-da-Silva
Walter Orlando Beys-da-Silva
Lucélia SantiLucélia Santi
Lucélia Santi
PTPaula Barros Terraciano
Paula Barros Terraciano
JGJorge Almeida Guimarães
Jorge Almeida Guimarães
Lonomia obliqua venom is nephrotoxic and acute kidney injury (AKI) is the main cause of death among envenomed victims. Mechanism underlying L. obliqua-induced AKI involves renal hypoperfusion, inflammation, tubular necrosis and loss of glomerular filtration and tubular reabsorption capacities. In the present study, we aimed to investigate the contribution of kallikrein to the hemodynamic instability, inflammation and consequent renal and vascular impairment Addition of L. obliqua venom to purified prekallikrein and human plasma in vitro or to vascular smooth muscle cells (VSMC) in culture, was able to generate kallikrein in a dose-dependent manner. Injected in rats, the venom induced AKI and increased kallikrein levels in plasma and kidney. Kallikrein inhibition by aprotinin prevented glomerular injury and the decrease in glomerular filtration rate, restoring fluid and electrolyte homeostasis. The mechanism underlying these effects was associated to lowering renal inflammation, with decrease in pro-inflammatory cytokines and matrix metalloproteinase expression, reduced tubular degeneration, and protection against oxidative stress. Supporting the key role of kallikrein, we demonstrated that aprotinin inhibited effects directly associated with vascular injury, such as the generation of intracellular reactive oxygen species (ROS) and migration of VSMC induced by L. obliqua venom or by diluted plasma obtained from envenomed rats. In addition, kallikrein inhibition also ameliorated venom-induced blood incoagulability and decreased kidney tissue factor expression These data indicated that kallikrein and consequently kinin release have a key role in kidney injury and vascular remodeling. Thus, blocking kallikrein may be a therapeutic alternative to control the progression of venom-induced AKI and vascular disturbances. The envenomation by venomous animals is considered a common and serious occupational disease, especially in rural areas of tropical developing countries. Its public health relevance has been largely ignored by medical authorities worldwide. Specifically in regions of southern and southeast Brazil, accidents with the venomous caterpillar Lonomia obliqua have been an emergent problem, not only for their high incidence rates, but also by the severity of the clinical consequences observed in envenomation cases. Frequently, envenomed victims present a severe hemorrhagic syndrome that can progress to acute kidney injury (AKI) and death. L. obliqua venom is highly nephrotoxic, AKI is the main cause of death between patients and its mechanisms are poorly understood. Even after the introduction of antivenom therapy in 1995, there was no reduction in the incidence of AKI. In this work we investigated the contribution of kallikrein to the hemodynamic instability, inflammation and consequent renal and vascular impairment during envenomation. A multidisciplinary approach was employed including methods of renal physiology/biochemistry, morphological and cell culture analysis. We believe the data presented here give new insights to the actual knowledge presenting kallikrein and the kinin system as key points to control the progression of renal disease, which may be explored as an approach complementary to serotherapy.

21 June 2023 in Fungal Biology
Verified
Journal Article
Closed access
LSLaura Rascovetzki Saciloto-De-Oliveira
Laura Rascovetzki Saciloto-De-Oliveira
LBLeonardo Broetto
Leonardo Broetto
CICamila Innocente-Alves
Camila Innocente-Alves
RRRafael Lopes da Rosa
Rafael Lopes da Rosa
YAYohana Porto Calegari Alves
Yohana Porto Calegari Alves
WBWalter Orlando Beys-da-Silva
Walter Orlando Beys-da-Silva

1 June 2022 in ImmunoHorizons
Verified
Journal Article
Open access
PDF file
Gaurav ShrivastavaGaurav Shrivastava
Gaurav Shrivastava
PVPaola Valenzuela
Paola Valenzuela
ACAndrezza Campos Chagas
Andrezza Campos Chagas
OKOlivia Kern
Olivia Kern
KBKarina Botello
Karina Botello
ECEric Calvo
Eric Calvo
Blood-feeding arthropods secrete potent salivary molecules, which include platelet aggregation inhibitors, vasodilators, and anticoagulants. Among these molecules, Alboserpin, the major salivary anticoagulant from the mosquito vector Aedes albopictus, is a specific inhibitor of the human coagulation factor Xa (FXa). In this study, we investigated the anti-inflammatory properties of Alboserpin, in vitro and in vivo. In vitro, Alboserpin inhibited FXa-induced protease-activated receptor (PAR)-1, PAR-2, PAR-3, VCAM, ICAM, and NF-κB gene expression in primary dermal microvascular endothelial cells. Alboserpin also prevented FXa-stimulated ERK1/2 gene expression and subsequent inflammatory cytokine release (MCP-1, TNF-α, IL-6, IL-8, IL-1β, IL-18). In vivo, Alboserpin reduced paw edema induced by FXa and subsequent release of inflammatory cytokines (CCL2, MCP-1, IL-1α, IL-6, IL-1β). Alboserpin also reduced FXa-induced endothelial permeability in vitro and in vivo. These findings show that Alboserpin is a potent anti-inflammatory molecule, in vivo and in vitro, and may play a significant role in blood feeding.

1 May 2021 in Toxicology Letters
Verified
Journal Article
Closed access
PZPamela Zanon
Pamela Zanon
SPSabrina Beal Pizzato
Sabrina Beal Pizzato
RRRafael Lopes da Rosa
Rafael Lopes da Rosa
PTPaula Barros Terraciano
Paula Barros Terraciano
JMJoão Alfredo Moraes
João Alfredo Moraes
MBMarkus Berger
Markus Berger